Navigation Links
Innovotech signs agreement for distribution of its bioFILM PA test in Israel
Date:8/12/2010

Edmonton, Alberta, July 27, 2010 Innovotech Inc. (TSX-V: IOT), a pioneer in the field of biofilm product development, has signed an exclusive distribution agreement with LevPharm Ltd of Israel to market and distribute its bioFILM PA test to hospitals and clinics within Israel.

"We are very excited to enter into this agreement with LevPharm, who recognize the significant impact the bioFILM PA test can have on improving patient care while reducing the cost burden to health care systems," said Ken Boutilier, President and CEO of Innovotech Inc. "The partnership with LevPharm illustrates their understanding of the importance of technologies for biofilm management, and further demonstrates Israel's leadership in embracing innovative products and solutions to enhance their health care system."

The current market capacity in Israel for acute infection treatment alone is estimated to be over 3,000 bioFILM PA tests per year.

bioFILM PA is the first diagnostic test to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based Pseudomonas aeruginosa infections.

Pseudomonas aeruginosa is a common bacterium responsible for many hospital acquired infections including ventilator-associated pneumonia and those found in patients with burns and wounds. It is also one of the major causes of lung infections in individuals with Cystic Fibrosis.

Over eighty percent of microbial infections in the body are caused by organisms in a biofilm state. Biofilm infections are known to be up to 4,000 times more resistant to antibiotics than the same organism in a free-floating state, which demonstrates why it is so critical to identify effective treatments early, such as through the bioFILM PA test.


'/>"/>

Contact: Ken Boutilier
ken.boutilier@innovotech.ca
780-448-0585
Innovotech Inc.
Source:Eurekalert

Page: 1

Related biology news :

1. Innovotech receives funding to advance environmentally friendly agricultural crop protection product
2. Syngenta Crop Protection Canada announces seed treatment project with Innovotech
3. Eurofins MWG Operon signs contract to supply oligonucleotides to Research Councils
4. Signs of reversal of Arctic cooling in some areas
5. Lake sturgeon have genes from parasite, signs of human STD
6. Phosphorous in sodas and processed foods accelerates signs of aging say Harvard scientists
7. Moffitt Cancer Center signs licensing agreement with Proteacel, LLC
8. Springer signs publishing agreement with ISOBM
9. Springer signs agreement with British Society of Research on Ageing
10. Copying mother natures designs
11. Plate-eating good: Université de Montréal professor designs edible tableware
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2017)... HANOVER, Germany , March 16, 2017 CeBIT 2017 - Against ... Continue Reading ... Used combined in one project, multi-biometric solutions ... ... Identification Systems) ...
(Date:3/7/2017)... -- Brandwatch , the leading social intelligence company, today announces ... to uncover insights to support its reporting, help direct future campaigns, ... leading youth charity will be using Brandwatch Analytics social listening and ... understanding of the topics and issues that are a priority for ... "Until ...
(Date:3/2/2017)... -- Summary This report provides all the ... its partnering interests and activities since 2010. Download ... Partnering Deals and Alliance since 2010 report provides an ... the world,s leading life sciences companies. On ... inclusion of the most up to date deal and ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... , March 27, 2017  Perthera,s Chief Bioinformatics Officer ... Subha Madhavan , Ph.D., will be speaking at ... Panels. On Monday, March 27, 2017, she will be ... More Usable for Research and Care" (from 10:30 a.m. ... 2017, she will be a participant in the "Making ...
(Date:3/27/2017)... NC (PRWEB) , ... March 27, 2017 , ... ... Clinical Trial Collaborations (CTC) conference presented by The Conference Forum in Boston on ... way they collaborate to drive improved clinical trial outcomes and bring them closer to ...
(Date:3/27/2017)... , March 27, 2017  Trovagene, Inc. (NASDAQ: ... its Chief Executive Officer, Bill Welch , will ... 4, 2017 at 9:00 AM EDT at the Essex ...  Bill Welch, and Chief Scientific Officer, Mark Erlander ... investors during the conference.   The presentation will ...
(Date:3/27/2017)... , March 27, 2017 Neurotrope, Inc. ... therapies for neurodegenerative diseases, including Alzheimer,s disease, today ... application to list the Company,s common stock on ... The NASDAQ Stock Market, a unit of the ... will ring the Opening Bell at the NASDAQ ...
Breaking Biology Technology: